Skip to main content
    S

    SAB Biotherapeutics Inc (SABS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.95
    -0.05 (-1.67%)

    Market Cap: $266.66M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    SAB Biotherapeutics Inc (SABS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    SAB Biotherapeutics (SABS) has a market cap of $266.66M and an enterprise value of $252.22M. Its share count is up 774.61% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 5.41% below the market cap, as cash exceeds debt.

    Market Cap$266.66M
    Enterprise Value$252.22M
    Latest price (Nov 17, 2026)$2.95

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 16.91% in the quarter ended Sep 30, 2026 and grew 217.33% a year over 2 years.

    Shares Outstanding93.24M
    Shares Change (YoY)+774.61%
    Shares Change (QoQ)+16.91%
    Share Count Growth (2Y CAGR)+217.33%

    Price Statistics

    The stock is down 8.95% over 52 weeks and trades 4.53% below its 50-day average.

    Beta (1Y)1.07
    52-Week Change-8.95%
    1-Month Change+13.46%
    3-Month Change-21.96%
    6-Month Change-16.90%
    5-Year Change-95.76%
    Total Return (1Y)-8.95%
    Total Return (3Y CAGR)-29.69%
    Total Return (5Y CAGR)-51.57%
    Return vs SPY (1Y)-36.11%
    Max Drawdown (1Y)-45.75%
    Max Drawdown (3Y)-88.58%
    Sharpe Ratio (1Y)-0.48
    Correlation with SPY (1Y)0.25
    50-Day Average$3.09
    200-Day Average$3.61
    52-Week Range$2.44 to $5.15
    RSI (14 Days)45.9
    Average Volume (20 Days)646.54K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.28x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.28x
    Quick Ratio7.28x
    Debt / Equity0.00x
    Interest Coverage50.20x

    Returns and Efficiency

    Return on equity is -38.18% over the last 12 months, against a 5-year average of -60.20%.

    Return on Equity (ROE)-38.18%
    Return on Assets (ROA)-34.17%
    ROE (5Y Average)-60.20%
    ROA (5Y Average)-35.54%
    ROIC (5Y Average)-28.38%

    Scores

    SABS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$763.30K
    Operating Income-$85.04M
    Pretax Income-$80.52M
    Net Income-$80.52M
    Reported EPS (TTM)-$1.28

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.51% of the $235.64M in total assets.

    Cash and Equivalents$14.44M
    Total Debt$0
    Net Cash$14.44M
    Net Cash Per Share$0.15
    Working Capital$92.94M
    Shareholder Equity$210.92M
    Book Value Per Share$2.26
    Total Assets$235.64M
    Total Liabilities$24.72M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.85M of capital spending, operating cash flow left -$58.76M of free cash flow.

    Operating Cash Flow-$53.91M
    Capital Expenditures$4.85M
    Free Cash Flow-$58.76M
    FCF Per Share-$0.65
    Depreciation and Amortization$3.17M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    SABS does not pay a dividend. Its free cash flow yield is -21.36%.

    FCF Yield-21.36%
    Buyback Yield0.00%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jan 5, 2024.

    Last Split DateJan 5, 2024
    Split TypeReverse split
    Split Ratio1:10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SABS

    What is SABS's market cap?

    SAB Biotherapeutics has a market cap of $266.66M. Its enterprise value, which adds debt and subtracts cash, is $252.22M.

    How many shares of SABS are outstanding?

    SAB Biotherapeutics has 93.24M shares outstanding. The count is up 774.61% from a year earlier.

    Does SABS pay a dividend?

    No. SAB Biotherapeutics does not pay a dividend.

    How much debt does SABS have?

    SAB Biotherapeutics has $0 of total debt and $14.44M of cash and equivalents, a net cash position of $14.44M.